Oncology

Selinexor is indicated for patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or CAR T-cell therapy.

In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for UB’s patient safety organization Empire State Patient Safety Assurance Network, discusses the role of RTU products in pharmacy.

Prescriptions for hormonal therapy medications increased in states that expanded Medicaid, according to a recent analysis.

Chronic liver disease and cirrhosis can contribute to the development of liver cancer, which affects approximately 33,000 individuals in the United States each year.

Study identifies potential risk factors for chemotherapy-induced febrile neutropenia in patients with cancer.

Lorlatinib approved for patients with ALK-positive metastatic NSCLC who have progressed on crizotinib (Xalkori) and at least 1 other ALK inhibitor for metastatic disease.

Top news of the week from Specialty Pharmacy Times.

All-oral direct-acting antivirals had a significant effect on the clinical and economic outcomes of patients with hepatitis C virus in the 4 years following the approval of these treatments.

New analysis examines the role of the HIV/AIDS epidemic in cancer survival rates among adolescents and young adults.

Study compares 2-year survival between patients with metastatic non-small cell lung cancer treated at academic and community centers.

The switchable CAR T system allows for complete control of the cancer-killing cells, which could improve the treatment’s safety.

Top news of the day from across the health care landscape.

California’s tobacco control programs have lowered lung cancer deaths 33% faster than the rest of the United States.

Officials with the FDA have approved talazoparib (Talzenna, Pfizer) for the treatment of HER2-negative locally advanced or metastatic breast cancer with germline BRCA (gBRCA) mutations.

Recent preclinical and population evidence shows cannabis modulates inflammatory and fibrotic processes in the liver, which is promising for treating the symptoms of hepatitis C virus.

Talazoparib, a poly ADP-ribose polymerase (PARP) inhibitor, is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer who are selected for the therapy based on an FDA-approved companion diagnostic.

Talazoparib is indicated for patients with known deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

Low-dose aspirin users may have a lower risk of developing ovarian cancer and hepatocellular carcinoma (HCC), according to 2 new studies published in JAMA Oncology.

Aspirin dose and duration of use may affect the risk of developing ovarian cancer and hepatocellular cancer.

Neoadjuvant therapy with a combination checkpoint blockade produced a high response rate among patients with melanoma.

Puerto Rico’s Hispanic population faces substantially different cancer risks compared with Hispanics in the continental United States.

Study highlights mechanism of endocrine resistance in estrogen receptor-positive breast cancers and potential therapeutic targets.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the emergence of CAR T-cell therapy as a groundbreaking oncology treatment.

Artificial intelligence tool can analyze images of patients’ lung tumors, specify cancer types, and identify altered genes driving abnormal cell growth.

Entrectinib showed a durable response and reduced tumors in patients with ROS1-positive non-small cell lung cancer.

A new report published in JAMA Oncology highlights the cost burden of utilizing prostate cancer screening and treatment in this age group.

The US Preventive Services Task Force recommends against routine screening for prostate cancer in men 70 years of age and older.

The CLL/SLL indication is a standard approval and the follicular lymphoma indication is an accelerated approval contingent on the results of a confirmatory trial

Officials with the FDA have approved duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.